Plerixafor augments PBSC collection, but the optimal approach for incorporating it into mobilization is uncertain. Forty-nine consecutive patients mobilized with G-CSF alone were analyzed, and a day 4 peripheral blood CD34 þ cell count of 0.015/ml was found to predict for a day 5 apheresis yield of 2 Â 10 6 CD34 þ progenitors/kg, our institutional minimum necessary for a single autologous transplant. On the basis of this relationship, a clinical guideline was developed which recommended pre-emptive use of plerixafor if the day 4 peripheral blood CD34 þ cell count was between 0.005 and 0.015/ml. A total of 166 consecutive subjects with lymphoma or plasma cell dyscrasias underwent G-CSF mobilization after adoption of this care pathway, and the mobilization failure rate was only 7% in patients managed per guideline. The median PBSC yield was 6.3 Â 10 6 CD34 þ progenitors/kg with G-CSF (day 4 peripheral blood CD34 þ cell40.015/ml) and 4.9 Â 10 6 CD34 þ progenitors/kg with G-CSF þ plerixafor (day 4 peripheral blood CD34 þ cell 0.005-0.015/ml). The median number of days of apheresis was 2 in both groups. This clinical guideline is an effective mobilization algorithm that minimizes mobilization failures, reduces poor apheresis yields, does not require risk factor identification and is simple to implement.
INTRODUCTION

Mobilization of CD34
þ cells into the peripheral blood for autologous hematopoietic SCT is traditionally accomplished by growth factor alone (G-CSF or GM-CSF) or by chemo-mobilization (growth factor plus chemotherapy). In large retrospective studies, one quarter of patients fail to achieve a minimally adequate mobilization, defined as collection of X2 Â 10 6 CD34 þ progenitors/kg. 1, 2 Additionally, one-half of the patients do not achieve the accepted target dose of X5 Â 10 6 CD34 þ progenitors/kg. 1 Poor mobilization has been associated with disease status, extent of prior therapy, radiation, older age and myelotoxic agents, such as melphalan, fludarabine and lenalidomide [3] [4] [5] [6] Plerixafor, a reversible CXCR4 antagonist, significantly increases the yield of CD34
þ peripheral blood cells in randomized studies, thereby enabling more patients to proceed to autologous transplant. 7, 8 In lymphoma, 59% of patients in the plerixafor þ G-CSF arm collected X5 Â 10 6 CD34 þ progenitors/kg compared with 20% in the placebo þ G-CSF arm (Po0.001). 8 Similarly in multiple myeloma, significant increases in the number of patients achieving minimal and optimal stem cell target collections were demonstrated. 8 Plerixafor-mobilized stem cells have engraftment kinetics and graft durability comparable to conventionally mobilized stem cells.
However, the optimal method to incorporate plerixafor into a mobilization algorithm is uncertain. Such an approach needs to balance the expense of plerixafor with the costs of prolonged apheresis, sub-optimal mobilization, risks of remobilization and delays in transplant. It should also be easy to implement by clinical staff. With these considerations in mind, a simple algorithm was established for plerixafor utilization. The institutional experience with this care pathway is described within this study.
MATERIALS AND METHODS
Adult patients who underwent autologous stem cell collection with G-CSF alone in the year before the Food and Drug Administration approval of plerixafor were identified through the Oregon Health & Science University stem cell processing laboratory database. G-CSF was administered subcutaneously at 10 mcg/kg daily. On day 4, peripheral blood CD34 þ cell count was obtained before G-CSF administration. On day 5, G-CSF was again administered and then PBSC collection was performed utilizing a Cobe Spectra apheresis unit (Terumo BCT, Lakewood, CO, USA) with a blood volume of 16 L. CD34 þ PBSC was assessed by flow cytometry in the collected stem cell product. Peripheral blood CD34 þ cell count on day 4 was correlated with day 5 CD34 þ PBSC yield by linear regression. Based on our 2008 data (Figure 1 below) , a utilization guideline for plerixafor was developed and approved by the Pharmacy and Therapeutics Committee. Peripheral blood CD34 þ cell count, PBSC collection yield and engraftment were prospectively collected. The clinical support staff (nurse coordinators) followed the laboratory results. If the collection criteria were met, they contacted the appropriate BMT physician for verbal release of the plerixafor order set. Patients undergoing autologous stem cell collection for lymphoma and multiple myeloma from January 2009 to July 2011 were identified from this prospectively maintained database for analysis. All patients undergoing stem cell collection gave written informed consent.
RESULTS
Forty-nine consecutive patients were identified who underwent autologous stem cell mobilization with G-CSF alone in the year before the Food and Drug Administration approval of plerixafor. Day 4 peripheral blood CD34 þ cell count was found to have a linear correlation with day 5 CD34
þ PBSC yield ( Figure 1 ). These results suggested that a day 4 peripheral blood CD34 þ cell count of 40.015/ml was necessary to yield X2 Â 10 6 CD34
progenitors/kg on day 5. Our institutional standard goal for collection is X3 Â 10 6 CD34 þ progenitors/kg per transplant, and our minimum acceptable number is X2 Â 10 6 CD34 þ progenitors/ kg per transplant. Apheresis was continued until the goal collection was reached, as long as peripheral blood CD34 þ count remained X0.010/ml.
On the basis of these results, a clinical guideline for plerixafor usage was developed for program use and received formal approval by the Pharmacy and Therapeutics Committee. Pre-emptive use of plerixafor was recommended for patients with myeloma or lymphoma undergoing autologous stem cell mobilization with G-CSF alone if the day 4 peripheral blood CD34 þ cell count was between 0.005 and 0.015/ml. A second dose of plerixafor was permitted if there was inadequate collection after the first dose. Patients with a day 4 blood CD34 þ of o0.005/ml were presumed unlikely to benefit from plerixafor and continued on G-CSF until the peripheral blood CD34
þ cells reached the range of 0.005-0.015/ml. If a minimum peripheral blood CD34 þ cell count of 0.005/ml was never reached, then the mobilization was aborted. Plerixafor could also be utilized to 'rescue' an ongoing apheresis course with inadequate yield, as judged by the BMT physician.
There were 185 patients identified who underwent autologous stem cell collection for lymphoma or plasma cell dyscrasias after implementation of this practice guideline. Nineteen patients underwent chemo-mobilization and are not included in this analysis. Of the remaining 166 patients, 108 patients had plasma cell dyscrasias and 58 patients had lymphoma ( Table 1) . Most of the plasma cell patients (72%) had received lenalidomide, and the median number of prior systemic therapies was 1. For lymphoma, the median number of prior regimens was 2. There were no significant differences in engraftment between patients who received plerixafor and those who did not (data not shown).
Of all the patients, 37% received plerixafor per guideline, 34% received G-CSF alone, 6% received plerixafor rescue and 22% were treated off-guideline (Table 2 ). There were no significant differences between plasma cell and lymphoma patients in mobilization outcomes. Of all patients who received plerixafor per guideline, the median yield was 4.9 Â 10 6 CD34 þ progenitors/ kg. The median number of days of apheresis was 2, and nearly half of patients (30 of 62) received a second dose of plerixafor. Of all patients who received only G-CSF per guideline, the median yield was 6.3 Â 10 6 CD34 þ progenitors/kg. There were no significant differences in number of days of apheresis or failed collections between G-CSF per guideline and plerixafor per guideline groups.
Thirteen patients did not reach the plerixafor threshold on day 4 but did reach it on day 5 after being continued on G-CSF. Only 10 (6% of total) patients received plerixafor to rescue a poor collection, and all of these 'rescue' patients mobilized at least 2 Â 10 6 CD34 þ progenitors/kg. Of lymphoma patients treated per guideline, 37 of 41 (90%) met our institutional target goal of X3 Â 10 6 CD34 þ progenitors/kg and 39 of 41 (95%) met our institutional minimum of X2 Â 10 6 CD34 þ progenitors/kg. Depending upon patient age and insurance, plasma cell patients underwent collection for either one or two transplants. For plasma cell patients collecting for one transplant and treated per guideline, 25 of 28 (89%) met our institutional target goal of X3 Â 10 6 CD34 þ progenitors/kg and 26 of 28 (93%) met our institutional minimum of X2 Â 10 6 CD34 þ progenitors/kg. For those collecting for two transplants, 45 of 54 (83%) met the requirement for two transplants and 50 of 54 (93%) collected enough for at least one transplant.
Of all patients, 36 (22%) were not treated per guideline (Table 3) . Fourteen patients received plerixafor off-guideline. In all cases, the peripheral blood CD34 was o0.005/ml. Only 3 of the 14 mobilizations failed to collect at least 2 Â 10 6 CD34 þ progenitors/kg. This minimum number was collected in every instance where the day 4 peripheral blood CD34 was 0.004/ml and in half of cases where the day 4 peripheral blood CD34 was 0.003/ ml. No cases were successful when peripheral blood CD34 þ cell count was o0.003/ml. In 22 cases, plerixafor was not given although the day 4 peripheral blood CD34 count met the guideline. In nearly all cases, plerixafor was not given due to lack of insurance approval. In 16 of the 22 cases where plerixafor was not given per guideline, the day 4 peripheral blood CD34 count was at least 0.010/ml. There was a trend towards lower median yield (4 versus 4.9) and greater risk of failing collection (9% versus 6%) in patients who did not receive plerixafor per guideline.
DISCUSSION
The optimal usage of plerixafor is controversial, and proper utilization needs to balance the cost of the drug versus the costs of additional collection days and risks of failed mobilizations. Each additional day of collection adds charges for apheresis, PBSC processing and freezing of PBSC, as well as risks of further procedures to the patient. Failed mobilizations result in significant costs for remobilization and treatment delays. We developed an institutional policy for plerixafor usage based on analysis of our historical series of G-CSF mobilizations that demonstrated a correlation between day 4 peripheral blood CD34 þ cell count and day 5 apheresis yield.
In over 2 years experience with this guideline, only 8% of all patients failed to collect at least 2 Â 10 6 CD34 þ progenitors/kg, the minimum necessary for a single transplant. Most patients (78%) were managed per guideline with 37% in the G-CSF only group and 34% in the pre-emptive plerixafor group. Relatively few patients received plerixafor as rescue (6%), indicating that there were relatively few cases of 'wasted' apheresis/processing attempts. Of patients managed according to guideline, the rate of failed collections was 7% (9 of 130). Patients who failed mobilization, when managed per guideline tended to be older, have been treated with more intensive therapy or have received prolonged courses of lenalidomide.
Thirty-six (22%) of all patients were managed off-guideline. In 22 cases, insurance coverage for plerixafor was not available. In the other 14 cases, patients received plerixafor even though the day 4 peripheral blood CD34 was o0.005/ml, and 11 were able to collect at least 2 Â 10 6 CD34 þ progenitors/kg. These results suggest that the lower limit of day 4 peripheral blood CD34 þ cell count for pre-emptive plerixafor usage could be decreased, at least to 0.003, which we have recently established as our new institutional standard (Figure 2) .
The cost of plerixafor needs to be judged against the cost of an additional day of collection. The average wholesale price in 2009 for one vial (1.2 ml of 20 mg/ml) of plerixafor is approximately $8000. 9 The total cost for one day of G-CSF, apheresis, PBSC processing and PBSC freezing is similar at about $7500 at our institution. These costs do not include the expense of remobilization or hazard of treatment delay. Although costs may differ among institutions, a reasonable approach is that the expense of plerixafor is acceptable if it saves at least one day of collection and cryopreservation.
Other investigators have examined the optimal usage of plerixafor. Some have suggested rescue plerixafor (for example, 'salvage' or 'just in time') as the best strategy. 10, 11 However, a rescue only approach would result in costly first-day attempts with very low yield. Identification of 'high-risk' patients for pre-emptive usage of plerixafor has also been suggested, 11 but a significant number of high-risk patients will mobilize adequately without plerixafor. Also, identification of high-risk patients often requires medical review beyond the expertise of support staff. Costa et al.
12 noted a similar relationship between day 4 peripheral blood CD34 þ cell count and stem cell yield but developed a more complicated cost-effect analysis without a ready for use algorithm. In contrast, our guideline is simpler for support staff to apply and other centers to implement.
Chemo-mobilization is an alternative strategy to G-CSF þ plerixafor. At our institution, chemo-mobilization is typically used for patients with significant malignancy burden at time of collection. G-CSF þ plerixafor has been calculated to be similar in cost to chemo-mobilization. 13 However, chemo-mobilization exposes the patient to the risks of neutropenic fever, hospital re-admission and unpredictable collections. It also can result in weekend collections that increases costs related to staffing.
In summary, we developed a straightforward clinical guideline for the usage of plerixafor based on the relationship between day 4 G-CSF-mobilized peripheral blood CD34 þ cell count and predicted day 5 apheresis yield. Following this guideline for the past 2 years resulted in few mobilization failures. It minimizes wasted apheresis days, does not rely on clinical history to identify 'high-risk' patients and is simple for clinical staff to implement. We continue to pursue means by which we can augment the cost efficiency of plerixafor utilization. We have modified our algorithm to create a lower threshold for utilization, and we have implemented high volume (20 L) apheresis after plerixafor to try to reduce the need for repeat dosing.
